Zymeworks Inc. reported $37M of revenue over the trailing twelve months, −70% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $37M (to Q2 2026). Net income: −$150M, trailing twelve months to Q2 2026. Free cash flow: −$121M, trailing twelve months to Q2 2026. Operating margin: −1178%, trailing twelve months to Q2 2026.

ZYMEZymeworks Inc.

Healthcare

$25.80+59% 1Y

$25.80

$16.1652 weeks$31.05

ZYME as reported

Zymeworks Inc. reported $37M of revenue over the trailing twelve months, −70% on the year before. 8 reported series are charted on this page, each one as filed.

$37M

Revenue, trailing twelve months · to Q2 2026 · −70% against the twelve months before

Net income: −$150M
Net income · +104% year on year · trailing twelve months to Q2 2026
Free cash flow: −$121M
Free cash flow · +198% year on year · trailing twelve months to Q2 2026
Operating margin: −1178%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ZYME, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$37M	−70%	Q2 2026
Net income	−$150M	+104%	Q2 2026
EPS	−$2.02	+106%	Q2 2026
Operating margin	−1178%	n/a	Q2 2026
Net margin	−1131%	n/a	Q2 2026
ROE	−75%	n/a	Q2 2026
ROA	−25%	n/a	Q2 2026
Free cash flow	−$121M	+198%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.